ClinicalTrials.gg

Program

tafolecimab

Also written as “IBI306”, “tafolecimab (a modified manufacturing process)” and “IBI306 450mg SC Q4W”.

Its studies are mostly in Hypercholesterolemia · Hyperlipoproteinemia Type II · Homozygous Familial Hypercholesterolemia, led by Innovent Biologics.

Furthest: phase 3, since Jul 22, 20198 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Innovent Biologics81 open or runningphase 3since Jul 22, 2019Nov 27, 2017none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 27, 2017First study: phase 1 study in HypercholesterolemiaFirst studyNCT03366688 · 58 enrolled · China
  2. Jan 22, 2019Phase 2 study in HypercholesterolemiaNCT03815812 · 60 enrolled · China
  3. Jul 22, 2019Phase 3 study in Homozygous Familial HypercholesterolemiaNCT04031742 · 18 enrolled · China
  4. Nov 25, 2019Phase 3 study in Heterozygous Familial HypercholesterolemiaNCT04179669 · 149 enrolled · China
  5. Feb 26, 2020Phase 3 study in HypercholesterolemiaNCT04289285 · 804 enrolled · China
  6. Jan 12, 2021Phase 3 study in HypercholesterolemiaNCT04709536 · 306 enrolled · China
  7. Mar 6, 2023Phase 1 study in Healthy Male SubjectsNCT05792917 · 166 enrolled · China
  8. Mar 11, 2026Phase 3 study in Hyperlipoproteinemia Type IINCT07473960 · 198 enrolled · China

TargetBeta

PCSK9 →read by rule
“A human immunoglobulin G2 (IgG2) monoclonal antibody directed against human proprotein convertase subtilisin/kexin type 9 (PCSK9), ”NCIt, by rule
“Subtilisin/kexin type 9 inhibitor”ChEMBL 37, by rule

Other programs on PCSK9

ProgramCompanyFurthest phaseStudies
alirocumabruleSanofiphase 448
evolocumabruleAmgenphase 445
inclisiranruleNovartisphase 437
lerodalcibeprulelib-therapeutics-llcphase 314
recaticimabruleJiangsu HengRui Medicinephase 37
QLC7401ruleQilu Pharmaceuticalphase 35
SAL003ruleShenzhen Salubris Pharmaceuticalsphase 33
VERVE-102Eli Lillyphase 22
DNV001rulehangzhou-dinovate-biotech-co-ltdphase 21
RBD7022ruleQilu Pharmaceuticalphase 12

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07473960Hyperlipoproteinemia Type II · China3Active, not recruitingSep 6, 2026198
NCT05792917Healthy Male Subjects · China1CompletedMar 26, 2023166
NCT04709536Hypercholesterolemia · China3CompletedNov 9, 2021306
NCT04289285Hypercholesterolemia · China3CompletedFeb 9, 2022804
NCT04179669Heterozygous Familial Hypercholesterolemia · China3CompletedJun 30, 2021149
NCT04031742Homozygous Familial Hypercholesterolemia · China3CompletedDec 30, 202118
NCT03815812Hypercholesterolemia · China2CompletedDec 25, 201960
NCT03366688Hypercholesterolemia · China1CompletedNov 5, 201858

How it is read

Names in the registry

  • “IBI306”, 8 entries
  • “tafolecimab (a modified manufacturing process)”, 1 entry
  • “IBI306 450mg SC Q4W”, 1 entry
  • “IBI306 600mg SC Q6W”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.